Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Oct;89(10):1055-60.
doi: 10.1111/j.1349-7006.1998.tb00496.x.

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite

T Noguchi  1 , S Ichii, S Morisada, T Yamaoka, Y Yanagi
Affiliations

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite

T Noguchi et al. Jpn J Cancer Res. 1998 Oct.

Abstract

The tissue distribution of a novel antitumor anthracycline antibiotic, amrubicin, was studied using seven human tumor xenografts implanted into nude mice, in order to identify the principal factors determining its therapeutic efficacy. We found a good correlation between the level of the metabolite amrubicinol in the tumor and the in vivo efficacy. High metabolic activity of amrubicin to amrubicinol was detected in tumor tissue homogenates, especially in cell lines highly sensitive to amrubicin in vivo. In contrast to amrubicin, the administration of amrubicinol showed less tumor-selective toxicity in these human tumor xenograft models. These data indicate that the tumor-selective metabolism of amrubicin to amrubicinol resulted in a tumor-selective disposition of amrubicinol, leading to good efficacy in in vivo experimental therapeutic models.

PubMed Disclaimer

References

    1. ) Ishizumi , K. , Ohashi , N. and Tanno , N.Stereospecific total synthesis of 9‐aminoanthracyclines: (+)‐9‐amino‐9‐deoxydaunomycin and related compounds . J. Org. Chem. , 50 , 4477 – 4485 ( 1987. ).
    1. ) Morisada , S. , Yanagi , Y. , Noguchi , T. , Kashiwazaki , Y. and Fukui , M.Antitumor activities of a novel 9‐aminoanthracycline (SM‐5887) against mouse experimental tumors and human tumor xenografts . Jpn. J. Cancer Res. , 80 , 69 – 76 ( 1989. ). - PMC - PubMed
    1. ) Yokota , S. , Negoro , S. , Yana , T. , Takada , Y. , Fukuoka , M.and The West Japan Lung Cancer Group. Phase II study of amrubicin (SM‐5887), a novel 9‐aminoanthracycline, in previously untreated patients with extensive‐stage small‐cell lung cancer (ES‐SCLC): a trial of The West Japan Lung Cancer Group . 8th World Conference on Lung Cancer , A1756 ( 1997. ).
    1. ) Hiraki , S. , Shinkai , T. , Furuse , K. , Fukuoka , M. , Ohnoshi , T. , Kimura , I.and The SM‐5887 Lung Cancer Study Group. A phase II of SM‐5887, a novel 9‐aminoanthracycline, for non‐small cell lung cancer . 18th International Congress of Chemotherapy , æ 726 ( 1993. ).
    1. ) Takigawa , N. , Ohnoshi , T. , Ueoka , H. , Kiura , K. and Kimura , I.Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines . Acta Med. Okayama , 46 , 249 – 256 ( 1992. ). - PubMed

MeSH terms

LinkOut - more resources